COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts Data were from a retrospective chart review of patients with ...

CD39 expression as a predictive biomarker for neoadjuvant treatment in muscle-invasive bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Lessons From Taxanes Versus Eribulin for First-Line Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the EMERALD Study ASCO Guidelines provide recommendations with ...

Cardiovascular mortality risk in primary penile cancer patients: A retrospective cohort study from 2000 to 2021. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium.

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma A total of 121 patients (previous ICI-treated cohort, n = 31, and each of ...

Clinical protocols to monitor efficacy of [177Lu]Lu-PSMA radiopharmaceutical therapy in metastatic castration-resistant prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Heterogeneity in subgroup reporting across clinical trials assessing systemic therapies in metastatic castration resistant prostate cancer: A report from a living systematic review. Final overall ...

Addition of darolutamide to first line treatment of metastatic castration-resistant prostate cancer (mCRPC): A randomized open label phase II trial (SAKK 08/23). This is an ASCO Meeting Abstract from ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy. Barriers to ...

Impact of androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy on health-related quality of life.

Sarcopenia as a marker to assess the surveillance necessity after a 5-year cancer-free period in patients who undergo radical cystectomy: A multi-institutional retrospective study.